Aspen sees higher profit, local unit robust

Africa’s biggest generic drug-maker, Aspen Pharmacare, said on Monday full-year headline earnings per share likely rose by 25% boosted by its South African operations.

Aspen, which is 19% owned by Britain’s GlaxoSmithKline, said earnings per share were expected to increased by between 30% and 35%, boosted by one-off gains.

Headline EPS is the main profit gauge in South Africa and strips out certain one-off items.

South African pharmaceutical companies have largely escaped the economic downturn, shielded partly by demand for antiretroviral drugs in the country that has one of the world’s heaviest HIV/Aids caseloads. — Reuters

Subscribe to the M&G

These are unprecedented times, and the role of media to tell and record the story of South Africa as it develops is more important than ever.

The Mail & Guardian is a proud news publisher with roots stretching back 35 years, and we’ve survived right from day one thanks to the support of readers who value fiercely independent journalism that is beholden to no-one. To help us continue for another 35 future years with the same proud values, please consider taking out a subscription.

Related stories


press releases

Loading latest Press Releases…

The best local and international journalism

handpicked and in your inbox every weekday